Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OrbusNeich Medical Group Holdings Buyback Yield % Chart
FRA:Q8T vs ISRG, BDX, MDLN: Buyback Yield % Comparison
For the Medical Instruments & Supplies subindustry, OrbusNeich Medical Group Holdings's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
OrbusNeich Medical Group Holdings Buyback Yield % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, OrbusNeich Medical Group Holdings's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where OrbusNeich Medical Group Holdings's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OrbusNeich Medical Group Holdings (FRA:Q8T) has a Buyback Yield % of 0.08 as of Jul. 22, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on OrbusNeich Medical Group Holdings and its competitors. This is 33% below median its historical median of 0.12. According to the industry distribution chart, OrbusNeich Medical Group Holdings ranks #115 out of 348 companies in the Medical Devices & Instruments industry, placing it in the top 33%.
Is OrbusNeich Medical Group Holdings' Buyback Yield % too high?
OrbusNeich Medical Group Holdings' current Buyback Yield % of 0.08 is 33% below median its 10-year median of 0.12. Based on the distribution chart, OrbusNeich Medical Group Holdings ranks #115 out of 348 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, OrbusNeich Medical Group Holdings has a GF Score™ of 96/100, reflecting its overall financial health beyond just this single metric.
How does OrbusNeich Medical Group Holdings' Buyback Yield % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, OrbusNeich Medical Group Holdings ranks #115 out of 348 companies for Buyback Yield %. This puts OrbusNeich Medical Group Holdings in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Medical Devices & Instruments company?
A good Buyback Yield % depends on the Medical Devices & Instruments industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on OrbusNeich Medical Group Holdings and its competitors. OrbusNeich Medical Group Holdings's current Buyback Yield % is 0.08, which is 33% below median its own 10-year median of 0.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OrbusNeich Medical Group Holdings stock overvalued right now?
OrbusNeich Medical Group Holdings (FRA:Q8T) has a current Buyback Yield % of 0.08. The stock's GF Value™ is €0.46, compared to a current price of €0.35 — trading 24.3% below its estimated fair value. The current Buyback Yield % is 0.08, which is 33% below median its 10-year median of 0.12. OrbusNeich Medical Group Holdings' overall GF Score™ is 96/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For OrbusNeich Medical Group Holdings (FRA:Q8T), the current Buyback Yield % is 0.08 as of Jul. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is OrbusNeich Medical Group Holdings (FRA:Q8T) Overvalued in 2026?
Based on GuruFocus' analysis, OrbusNeich Medical Group Holdings stock appears to be undervalued.
The current stock price of €0.35 is trading 24.3% below its estimated GF Value™ of €0.46.
Key valuation signals for FRA:Q8T:
Buyback Yield %: 0.08 (33% below median its 10-year median of 0.12)
GF Value™: €0.46 vs. price of €0.35 (24.3% below fair value)
No single metric tells the full story. See the FRA:Q8T stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
OrbusNeich Medical Group Holdings Business Description
OrbusNeich Medical Group Holdings Ltd is an investment holding company. The Company principally engaged in the manufacturing, trading, sales and marketing of medical devices/instruments used for the treatment of coronary and peripheral vascular diseases. The group has only one operating segment. The company has presence in APAC, EMEA, Japan, United States, The PRC, and Others of which majority of revenue comes from APAC.
96GF Score
Get the complete analysis for FRA:Q8T
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:Q8T has been successfully added to your 
